Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 119478-56-7] Meropenemtrihydrate

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-13678A
Brand:	MCE
CAS:	119478-56-7

Overview

MDL	MFCD08600005
Molecular Weight	437.51
Molecular Formula	C17H31N3O8S
SMILES	O=C(C(N12)=C(S[C@@H]3CN[C@H](C(N(C)C)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O.O.O.O

For research use only. We do not sell to patients.

8 Publications Citing Use of MCE

[1]Nat Microbiol. 2023 Feb 9.
[2]Nat Commun. 2022 Mar 2;13(1):1116.
[3]J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858.
[4]Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00414-18.
[5]Int J Antimicrob Agents. 2018 Aug;52(2):269-271.
[6]Open Forum Infect Dis. 2023 Jan 27.
[7]Spectrochim Acta A Mol Biomol Spectrosc. 2020 Apr 5;230:118066.
[8]Infect Drug Resist. 2021 Jun 30;14:2499-2507.

Summary

Meropenem trihydrate (SM 7338 trihydrate) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem trihydrate has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL) ^[1] ^[2] .

In Vitro

Meropenem is intrinsically stable to dehydropeptidase-1 (DHP-1) degradation and Meropenem acts by inhibiting bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs). Meropenem possesses broad-spectrum in vitro activity, which includes activity against many Gram-positive, Gram-negative and anaerobic bacteria; Meropenem lacks activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus and Stenotrophomonas maltophilia ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Meropenem (60 mg/kg; intraperitoneal injection; once; SD rats) treatment significantly reduces the incidence of pancreatic infection ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (250-350 g) induced acute necrotizing pancreatitis ^[3]
Dosage:	60 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Significantly reduced the incidence of pancreatic infection.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00752219	Pfizer	Complicated Intra-abdominal Infections	March 31, 2009	Phase 2
NCT01044719	Imperial College London	Cystic Fibrosis	January 2010	Phase 4
NCT05058105	Qilu Pharmaceutical Co., Ltd.	Healthy	October 8, 2020	Phase 1
NCT01429259	Joseph Kuti\|Thrasher Research Fund\|Hartford Hospital	Cystic Fibrosis\|Pneumonia\|Pseudomonas Aeruginosa Infection	February 2012	Phase 4
NCT03136796	University Hospital Hradec Kralove	Critical Illness	May 2, 2017
NCT02506686	Huashan Hospital	Central Nervous System Infections	September 2008	Phase 4
NCT02463747	Tel-Aviv Sourasky Medical Center	Fever\|Febrile Neutropenia	June 2015	Phase 4
NCT03174184	Johns Hopkins University	Tuberculosis, Pulmonary	August 23, 2017	Phase 2
NCT04629378	TASK Applied Science	Tuberculosis	August 17, 2020	Phase 2
NCT05578586	Oslo University Hospital	Drug Effect	December 14, 2021	Not Applicable
NCT03970265	Ludwig-Maximilians - University of Munich	Lung Transplantation	August 15, 2019
NCT05426499	Poznan University of Medical Sciences\|University at Buffalo\|The Greater Poland Cancer Centre	Population Modeling of Anti-infective Drugs	October 1, 2021
NCT02142751	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\|Spanish Network for Research in Infectious Diseases	Infection Due to ESBL Escherichia Coli	July 2014	Phase 3
NCT03182504	Hoffmann-La Roche	Gram-negative Bacterial Infections	June 15, 2017	Phase 1
NCT04478721	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\|Spanish Network for Research in Infectious Diseases\|SCReN Spanish research Network- CTU-HUVR	Bacteremia	December 15, 2020	Phase 3
NCT02213796	Sutep Jaruratanasirikul\|Prince of Songkla University	Initial Phase of Severe Sepsis and Septic Shock	January 2013	Phase 4
NCT05134298	Karolinska University Hospital	Antibiotic Pharmacokinetics	November 1, 2019
NCT01158937	Unity Health Toronto\|Sunnybrook Health Sciences Centre\|University of Toronto	Cystic Fibrosis Pulmonary Exacerbation	May 2010	Not Applicable
NCT05393505	The University of Hong Kong\|Queen Mary Hospital, Hong Kong	Neutropenic Fever	October 24, 2022	Phase 4
NCT03858387	Prince of Songkla University	Critical Illness\|Bacterial Infections	September 1, 2018
NCT01297842	Mahidol University	Drug Safety	May 2011	Phase 4
NCT03230838	Merck Sharp & Dohme LLC	Complicated Urinary Tract Infection\|Pyelonephritis	April 26, 2018	Phase 2
NCT00318994	Pfizer	Pancreatitis	February 2002	Phase 4
NCT03344627	Mahidol University	Sepsis\|Septic Shock\|Critical Illness\|Carbapenem\|Pharmacokinetic\|Pharmacodynamic\|Clinical Outcome\|Organ Failure, Multiple\|Morality	November 27, 2017	Not Applicable
NCT02475733	Pfizer	Complicated Intra-abdominal Infections	August 1, 2015	Phase 2
NCT03217136	Merck Sharp & Dohme LLC	Complicated Intra-Abdominal Infection	April 3, 2018	Phase 2
NCT02788240	Institute of Liver and Biliary Sciences, India	Acute on Chronic Liver Failure	May 1, 2016	Not Applicable
NCT01445678	Cubist Pharmaceuticals LLC	Complicated Intra-abdominal Infection	December 23, 2011	Phase 3
NCT04771884	Shandong University\|Children´s Hospital of Chongqing Medical University	Bacterial Meningitis\|Augmented Renal Clearance	October 1, 2020
NCT03671967	Rambam Health Care Campus\|Rabin Medical Center\|University of Modena and Reggio Emilia\|Tel Aviv Medical Center\|Meir Medical Center\|Soroka University Medical Center\|The Chaim Sheba Medical Center\|McGill University Health Centre+Research Institute of the McGill University Health Centre\|Jewish General Hospital\|Canadian Institutes of Health Research (CIHR)\|Hadassah Medical Organization	Beta Lactam Resistant Bacterial Infection\|Enterobacteriaceae Infections\|Bacteremia	May 1, 2019	Phase 4
NCT00307099	National Institute of Allergy and Infectious Diseases (NIAID)	Bacterial Infection	October 2006	Phase 3
NCT02047773	University of Edinburgh\|NHS Lothian	Bronchiectasis	January 2014	Phase 4
NCT04370145	Tongji Hospital\|Shanghai Children´s Hospital	Cholangitis, Secondary Biliary\|Treatment Compliance\|Antibodies Drug Specific	May 1, 2021	Phase 4
NCT02176122	The University of Queensland\|International Society of Chemotherapy\|Australian Society for Antimicrobials\|Queensland Clinical Trials & Biostatistics Centre\|Australasian Society for Infectious Diseases	Bloodstream Infections	February 2014	Phase 4
NCT01551394	PENTA Foundation\|Chiesi Farmaceutici S.p.A.	Sepsis	September 2012	Phase 3
NCT03507751	Medical University of Lublin\|University of Warmia and Mazury in Olsztyn	Infection\|Renal Failure	April 2, 2018
NCT01667094	The Alfred	Cystic Fibrosis	September 2012	Phase 4
NCT04238390	The University of Queensland\|Merck Sharp & Dohme LLC	Bacteremia Caused by Gram-Negative Bacteria	January 2022	Phase 3
NCT03452839	Università Vita-Salute San Raffaele	Antibiotic Resistant Infection\|Critical Illness	June 5, 2018	Phase 4
NCT02437045	The University of Queensland	Bloodstream Infections	April 2015	Phase 4
NCT00579956	University of Oxford\|Mahidol University\|Wellcome Trust	Melioidosis	December 2007	Not Applicable
NCT01147640	Cubist Pharmaceuticals LLC	Complicated Intra-abdominal Infection	June 25, 2010	Phase 2
NCT05340530	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Infections	April 2022	Phase 1
NCT02609646	Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva	Critical Illness\|Infection	January 2016
NCT00771316	Merck Sharp & Dohme LLC	Urinary Tract Infections	December 2008	Phase 3
NCT02486627	Achaogen, Inc.	Complicated Urinary Tract Infection\|Acute Pyelonephritis	January 11, 2016	Phase 3
NCT04816968	Ospedale San Carlo Borromeo\|Associazione Oncologica Milanese AmoLaVita ONLUS	Severe Bacterial Infections	September 2021	Phase 1
NCT01992198	Erzhen Chen\|RenJi Hospital\|Ruijin Hospital	Pancreatitis,Acute Necrotizing	July 2012	Phase 4
NCT03036826	University Hospital Tuebingen	Acute Kidney Insufficiency\|Anti-Infective Agent Toxicity	June 2019
NCT02349841	TASK Applied Science\|Eduardo Mondlane University\|GlaxoSmithKline\|Barcelona Centre for International Health Research\|Research Center Borstel	Pulmonary Tuberculosis	September 2014	Phase 2
NCT04132115	Azienda Sanitaria-Universitaria Integrata di Udine	Therapeutic Drug Monitoring\|Subarachnoid Hemorrhage\|Intracerebral Hemorrhage	October 1, 2019
NCT05392634	N.N. Petrov National Medical Research Center of Oncology\|The Foundation for Cancer Research Support (RakFond)	Bladder Cancer	February 2, 2022	Phase 3
NCT01570192	University of Florida	Bacterial Pneumonia	September 2010	Phase 2
NCT02615041	Sutep Jaruratanasirikul\|Prince of Songkla University	Ventilator-Associated Pneumonia	January 2004	Phase 4
NCT05204368	Sinovent Pty Ltd.	Complicated Urinary Tract Infection Including Acute Pyelonephritis	March 2022	Phase 3
NCT00534287	Kompetenznetz Sepsis\|AstraZeneca\|Bayer	Severe Sepsis\|Septic Shock	October 2007	Phase 3
NCT00435305	University Hospital Tuebingen	Pneumonia\|Bacteremia	November 2006
NCT00462878	PETHEMA Foundation	Allogenic Blood Stem Cell Transplantation\|Febrile Neutropenia	November 2002
NCT04154722	Ziauddin University	Typhoid Fever	June 20, 2019	Phase 4
NCT04489459	Al-Azhar University	Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae	September 21, 2019	Phase 4
NCT01499290	Pfizer\|Forest Laboratories	Complicated Intra-Abdominal Infection	March 2012	Phase 3
NCT00061438	Pfizer	Pancreatitis, Acute Necrotizing	February 2003	Phase 4
NCT02149329	Amsterdam UMC, location VUmc\|ZonMw: The Netherlands Organisation for Health Research and Development\|FondsNutsOhra	Febrile Neutropenia\|Hematological Malignancy	December 2014	Phase 4
NCT01597973	University of Michigan	Pneumonia\|Blood Stream Infection	October 6, 2012	Phase 3
NCT02820987	Centre Hospitalier Universitaire de Besancon	Septic Shock	September 1, 2016	Phase 3
NCT02732327	Forest Laboratories	Neoplasms\|Febrile Neutropenia	May 17, 2016	Phase 2
NCT00619710	Pfizer	Skin Infection\|Abscess\|Cellulitis	February 2001	Phase 3
NCT03140826	University Hospital Tuebingen\|University Hospital of Cologne	Antibiotic Selection Pressure	January 30, 2018
NCT01726023	Pfizer	Complicated Intra-abdominal Infection	January 2013	Phase 3
NCT03032380	Shionogi\|Shionogi Inc.	Healthcare-associated Pneumonia (HCAP)\|Hospital Acquired Pneumonia (HAP)\|Ventilator Associated Pneumonia (VAP)	October 24, 2017	Phase 3
NCT03157388	University of Aarhus	Alcoholic Hepatitis	June 1, 2017	Not Applicable
NCT04402359	King Abdul Aziz Specialist Hospital	Ventilator Associated Pneumonia	July 5, 2018
NCT03174795	Hoffmann-La Roche	Urinary Tract Infections	July 11, 2017	Phase 1
NCT01970371	Achaogen, Inc.\|Department of Health and Human Services	Bloodstream Infections (BSI) Due to CRE\|Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE\|Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE\|Complicated Urinary Tract Infection (cUTI) Due to CRE\|Acute Pyelonephritis (AP) Due to CRE	September 16, 2014	Phase 3
NCT02784704	Tetraphase Pharmaceuticals, Inc.\|La Jolla Pharmaceutical Company	Complicated Intra-abdominal Infections\|Complicated Appendicitis	October 13, 2016	Phase 3
NCT01554124	PENTA Foundation\|Chiesi Farmaceutici S.p.A.	Meningitis	February 2013	Phase 1\|Phase 2
NCT04876430	Hospital de Clinicas de Porto Alegre\|Conselho Nacional de Desenvolvimento Científico e Tecnológico	Carbapenem-Resistant Enterobacteriaceae Infection\|Bloodstream Infection	May 4, 2021	Phase 2\|Phase 3
NCT03019965	Coordinación de Investigación en Salud, Mexico\|Instituto Mexicano del Seguro Social\|Hospital Infantil de Mexico Federico Gomez\|Hospital Regional de Alta Especialidad del Bajio	Sepsis	February 1, 2017	Not Applicable
NCT04553367	King Abdul Aziz Specialist Hospital	ARDS\|Septic Shock	July 2, 2020	Phase 1\|Phase 2
NCT05042271	Prince of Songkla University	Autoimmune Diseases	January 1, 2020
NCT03645668	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Sepsis	January 30, 2018	Phase 4
NCT03891433	Universidad del Norte	Urinary Tract Infections\|Enterobacteriaceae Infections\|Infection Due to ESBL Bacteria\|Carbapenem\|Escherichia Coli Infection\|Klebsiella Pneumoniae Infection\|Clinical Trial\|Drug Resistance, Bacterial	April 1, 2019	Phase 4
NCT04233996	Hospital Universitari de Bellvitge\|Institut d´Investigació Biomèdica de Bellvitge\|Instituto de Salud Carlos III	Febrile Neutropenia	June 5, 2019	Phase 4
NCT02212392	Benazir Bhutto Hospital, Rawalpindi	Acute Pancreatitis	January 2013	Phase 1\|Phase 2
NCT03543436	Assistance Publique - Hôpitaux de Paris\|Groupe Hospitalier Paris Saint Joseph\|French National Network of Clinical Research in Infectious Diseases (RENARCI)	Urinary Tract Infections	January 4, 2019	Phase 3
NCT01808092	Pfizer	Nosocomial Pneumonia (NP)\|Ventilator-associated Pneumonia (VAP)	April 2013	Phase 3
NCT05565222	Assistance Publique - Hôpitaux de Paris	Sepsis\|Septic Shock	January 2023	Phase 3
NCT00438269	Canadian Critical Care Trials Group\|The Physicians´ Services Incorporated Foundation	Nosocomial Infection\|Pneumonia\|Systemic Inflammatory Response Syndrome\|Critical Illness\|Pyrexia	February 2003	Phase 2
NCT05355350	Rambam Health Care Campus\|The Chaim Sheba Medical Center\|Rabin Medical Center\|Hadassah Medical Organization	Beta Lactam Resistant Bacterial Infection\|Enterobacteriaceae Infections\|Bacteremia	July 1, 2022	Phase 4
NCT01732250	Mical Paul\|European Commission\|Rabin Medical Center	Gram-Negative Bacterial Infections	March 2013	Phase 4
NCT00891423	Austin Health	Sepsis	April 2009	Not Applicable
NCT00621192	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|The Emmes Company, LLC	Necrotizing Enterocolitis\|Intra-abdominal Infection	June 2008	Phase 1\|Phase 2
NCT01944319	Qingtao Zhou\|Peking University Third Hospital	Lower Respiratory Tract Infection	July 2013	Phase 4
NCT01110382	Janssen Research & Development, LLC	Abscess, Intra-Abdominal\|Abdominal Abscess\|Abdomen, Acute\|Abdominal Pain\|Appendicitis\|Rupture\|Infection\|Intestinal Perforation\|Peritonitis\|Ileus	December 2010	Phase 3
NCT03477422	Venus Remedies Limited	Urinary Tract Infection Complicated\|Acute Pyelonephritis	January 11, 2014	Phase 3
NCT03571711	Hannover Medical School	Peritonitis Bacterial\|Liver Cirrhosis	June 28, 2018
NCT02972255	Hoffmann-La Roche	Healthy Volunteers	October 31, 2016	Phase 1
NCT00153634	Seattle Children´s Hospital\|Cystic Fibrosis Foundation	Cystic Fibrosis\|Chronic Bronchitis	March 2004	Not Applicable
NCT03485950	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|National Cancer Institute (NCI)	Other Infectious Diseases	May 16, 2018	Phase 2
NCT02456974	University Hospital, Ghent\|University Hospital, Antwerp\|Queen Fabiola Children´s University Hospital, Brussels	Pharmacokinetics\|Amoxicillin-clavulanate\|Piperacillin-tazobactam\|Vancomycin\|Teicoplanin\|Meropenem\|Ciprofloxacin\|Amikacin	May 2012
NCT04979806	Wockhardt\|Medpace, Inc.	Complicated Urinary Tract Infection\|Acute Pyelonephritis	August 28, 2022	Phase 3
NCT03830333	Merck Sharp & Dohme LLC	Complicated Intra-abdominal Infections	March 20, 2019	Phase 3
NCT02070757	Cubist Pharmaceuticals LLC	Healthcare-Associated Pneumonia\|Ventilator-Associated Pneumonia\|Lung Diseases	September 2, 2014	Phase 3
NCT02840136	University Ghent\|King Baudouin Foundation\|Belgische Vereniging voor Strijd tegen Mucoviscidose	Cystic Fibrosis	February 2016	Not Applicable
NCT01381562	GlaxoSmithKline	Infections, Intestinal	October 3, 2011	Phase 2
NCT03840148	Venatorx Pharmaceuticals, Inc.	Urinary Tract Infections\|Acute Pyelonephritis	August 7, 2019	Phase 3
NCT05226923	Sumitovant Biopharma, Inc.	Bacterial Infections	January 12, 2022	Phase 1
NCT00318552	Pfizer	Sepsis	January 2002	Phase 4
NCT03630081	Wockhardt\|Medpace Finland OY	Complicated Urinary Tract Infection\|Acute Pyelonephritis	August 25, 2019	Phase 3
NCT01292031	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\|European Commission	Ventilator-associated Bacterial Pneumonia	May 2012	Phase 3
NCT04257838	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Sepsis\|Septic Shock	February 15, 2020
NCT04671589	Mabaret Al-Asafara Hospitals	Drug Toxicity	June 2021	Phase 4
NCT04555798	Mohamed Gaber Allam\|King Abdul Aziz Specialist Hospital	Patients With Respiratory Failure and Shocked	February 1, 2022	Phase 1\|Phase 2
NCT01455246	University of Padova	Cirrhosis\|Ascites\|Nosocomial Spontaneous Bacterial Peritonitis	October 2010	Phase 2\|Phase 3
NCT04983901	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Hematopoietic and Lymphoid Cell Neoplasm\|Malignant Solid Neoplasm	September 14, 2021	Phase 2
NCT03717350	Hellenic Institute for the Study of Sepsis	Sepsis	October 27, 2018	Phase 2\|Phase 3
NCT05105035	Arrevus Inc.\|Aceragen	Melioidosis	June 14, 2022	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 228.57 mM ; Need ultrasonic)

H ₂ O : 12.5 mg/mL ( 28.57 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2857 mL	11.4283 mL	22.8566 mL
5 mM	0.4571 mL	2.2857 mL	4.5713 mL
10 mM	0.2286 mL	1.1428 mL	2.2857 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (228.57 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] L Slaney, et al. In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya. J Antimicrob Chemother. 1989 Sep;24 Suppl A:183-6.
[2] George G Zhanel, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52.
[3] Umit Ateskan, et al. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas. 2003 Oct;27(3):247-52.

Synonyms

1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, hydrate (1:3), (4R,5S,6S)-

1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, trihydrate, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]-

1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, trihydrate, (4R,5S,6S)-

Meropenem trihydrate

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart